Federal contract award
75N93023F00004
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN43 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | 75N93019D00031 |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $4.6M |
| Current contract value | $4.6M |
| Potential contract value / ceiling | $4.6M |
| Start date | Aug 23, 2023 |
| Current end date | Jul 22, 2026 |
| Potential end date | Jul 22, 2026 |
| Latest award activity | May 10, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 10, 2026 | P00007 | $0 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS |
| Dec 8, 2025 | P00006 | $1.2M | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS |
| Jul 21, 2025 | P00005 | $0 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS |
| May 28, 2025 | P00004 | $0 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS |
| Apr 24, 2025 | P00003 | $0 | EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI FULL TERMINATION |
| Apr 23, 2025 | P00002 | $0 | EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI FULL TERMINATION |
| Apr 12, 2024 | P00001 | $321.8K | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS |
| Aug 23, 2023 | 0 | $3.1M | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.